Corient Private Wealth LP Invests $2.01 Million in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Corient Private Wealth LP acquired 24,244 ANI Pharmaceuticals shares worth approximately $2.01 million, representing a 0.11% stake. Institutional investors collectively own 76.05% of the company.
• ANI Pharmaceuticals exceeded quarterly expectations, reporting $2.21 in EPS versus the $2.04 consensus and revenue of $266.04 million, up 25.8% year over year.
• Analyst sentiment remains favorable but mixed, with a consensus “Moderate Buy” rating and an average price target of $105.83, while the stock recently traded at $73.06.

Corient Private Wealth LP acquired a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 24,244 shares of the specialty pharmaceutical company's stock, valued at approximately $2,007,000. Corient Private Wealth LP owned 0.11% of ANI Pharmaceuticals as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in ANI Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company's stock valued at $103,022,000 after buying an additional 27,598 shares in the last quarter. Penn Capital Management Company LLC boosted its stake in shares of ANI Pharmaceuticals by 2,058.9% during the 4th quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company's stock worth $10,858,000 after acquiring an additional 131,030 shares in the last quarter. CenterBook Partners LP acquired a new stake in shares of ANI Pharmaceuticals in the 4th quarter worth approximately $1,518,000. NFJ Investment Group LLC purchased a new position in ANI Pharmaceuticals in the 2nd quarter valued at approximately $2,766,000. Finally, Jupiter Topco LLC purchased a new position in ANI Pharmaceuticals in the 2nd quarter valued at approximately $6,597,000. Hedge funds and other institutional investors own 76.05% of the company's stock.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $73.06 on Thursday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The business's fifty day moving average price is $79.12 and its two-hundred day moving average price is $78.53. The stock has a market cap of $1.68 billion, a PE ratio of 15.75 and a beta of 0.45. ANI Pharmaceuticals, Inc. has a one year low of $70.15 and a one year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, topping analysts' consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The company had revenue of $266.04 million during the quarter, compared to analysts' expectations of $260.13 million. During the same period in the previous year, the firm posted $1.80 earnings per share. The business's revenue for the quarter was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current fiscal year.

Analyst Ratings Changes

ANIP has been the topic of a number of research analyst reports. Zacks Research downgraded ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 14th. Wall Street Zen downgraded ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Canaccord Genuity Group decreased their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a research report on Monday, August 10th. Weiss Ratings cut shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Tuesday, August 11th. Finally, Guggenheim dropped their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating for the company in a report on Monday, August 10th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $105.83.

Insider Activity

In related news, Director Thomas Haughey sold 2,000 shares of ANI Pharmaceuticals stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.88, for a total transaction of $161,760.00. Following the completion of the sale, the director owned 38,878 shares in the company, valued at approximately $3,144,452.64. This trade represents a 4.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the business's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $75.48, for a total transaction of $37,740.00. Following the completion of the transaction, the vice president directly owned 74,424 shares of the company's stock, valued at $5,617,523.52. The trade was a 0.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 27,237 shares of company stock worth $2,155,105 in the last quarter. Corporate insiders own 8.10% of the company's stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source